| Promacta (eltrombopag) / Novartis |
NCT06458803: Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease |
|
|
| Completed | N/A | 52 | NA | Eltrombopag, Promacta | Tongji Hospital | Refractory Thrombocytopenia, Connective Tissue Diseases | 05/23 | 11/23 | | |
ChiCTR1900021211: A pilot study for evaluation of the safety and efficacy of eltrombopag plus pulsed dexamethasone as first line therapy for subjects with idiopathic thrombocytopenic purpura (ITP) |
|
|
| Recruiting | N/A | 60 | | eltrombopag 25-75mg daily for 3 months plus pulsed dexamethasone, 40mg daily for 4 days repeated every 4 weeks for 1-3 courses | University Hospital, Macau; University Hospital, Macau, Novartis Pharmaceuticals (HK) Ltd | immune thrombocytopenia (ITP) | | | | |
NCT03902041: The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT |
|
|
| Not yet recruiting | N/A | 160 | RoW | Eltrombopag | Shandong Provincial Hospital | Allogeneic Hematopoietic Stem Cell Transplantation, Eltrombopag | 04/22 | 10/22 | | |
NCT04214951: A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia |
|
|
| Active, not recruiting | N/A | 100 | RoW | Eltrombopag, Recombinant human thrombopoietin (rh-TPO) | Peking University People's Hospital | Corticosteroid-resistant or Relapsed ITP | 08/22 | 12/22 | | |
ChiCTR2000036040: A prospective clinical study of eltrombopag in the improvement of thrombocytopenia in hemophagocytic lymphohistiocytosis patients |
|
|
| Not yet recruiting | N/A | 40 | | eltrombopag 50mg po qd ;rhTPO 15000iu ih qd | Beijing Friendship Hospital Affiliated to Capital Medical University; Beijing Friendship Hospital Affiliated to Capital Medical University, Self financing | hemophagocytic lymphohistiocytosis | | | | |
ChiCTR2000035473: Efficacy and Safety of Cyclosporine A Combined with Eltrombopag in Adults with Lower-risk Myelodysplastic Syndrome---A prospective , open-label, controlled, multicenter study |
|
|
| Not yet recruiting | N/A | 264 | | CsA ;CsA+Epag | The Sixth People's Hospital Affiliated to Shanghai Jiaotong University; Rujin Hospital North Campus, Shanghai Jiao Tong University School of Medicine, Shanghai Shenkang Hospital Development Center's Three-year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals (2020-2022) Major Clinical Research Projects | Myelodysplastic Syndrome | | | | |
NCT04837703: MAP to Provide Access to Eltrombopag, for Treatment of Patients With Medically Significant Thrombocytopenia |
|
|
| Available | N/A | | NA | Eltrombopag | Novartis Pharmaceuticals | Thrombocytopenia | | | | |
NCT06137105: Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura |
|
|
| Not yet recruiting | N/A | 100 | NA | eltrombopag and romiplastim, Corticosteroids | Assiut University, Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | ITP - Immune Thrombocytopenia | 12/26 | 12/26 | | |
ChiCTR2200062120: Synergistic effect of low-dose cyclosporine A on eltrombopag in the management of multiline failed immune thrombocytopenia patients: a single-center, self-control study |
|
|
| Not yet recruiting | N/A | 50 | | low-dose cyclosporine A combined with EPAG | Zhejiang Provincial Hospital of Traditional Chinese Medicine; Zhejiang Provincial Hospital of Traditional Chinese Medicine, Self-funded，National Key Disciplines Funding | immune thrombocytopenia | | | | |
NCT06479291: The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP |
|
|
| Recruiting | N/A | 126 | RoW | Hydroxychloroquine Oral Tablet, Hydroxychloroquine, Eltrombopag, Eltrombopag pill | Yunfeng Cheng, Shanghai Zhongshan Hospital, Shanghai Jinshan Hospital, Zhongshan Qingpu Hospital, Fudan University, Zhongshan Wusong Hospital, Fudan University, Macau University of Science and Technology Hospital, Health and Humanity Research Centre, Hongkong, Dr. Stanley Ho Medical Foundation, Macau | Immune Thrombocytopenia With Positive ANA Antibodies | 01/26 | 12/26 | | |
| Recruiting | N/A | 10 | Japan | eltrombopag | Novartis Pharmaceuticals | Aplastic Anemia | 03/29 | 03/29 | | |
| Enrolling by invitation | N/A | 197 | Europe | ATGAM plus CsA with or without Eltrombopag, hATG+CsA +/- Revolade | European Group for Blood and Marrow Transplantation | Severe Aplastic Anemia | 12/33 | 12/34 | | |
